Ultrasound Workspace (UWS 6.0) vs ElucidVivo A.3
AI Verdict
Choose Ultrasound Workspace (UWS 6.0) if…
Choose Philips Ultrasound Workspace (UWS 6.0) if your primary need is to streamline and standardize echocardiography workflows, particularly for complex 2D and 3D cardiac ultrasound analysis. This tool excels in providing AI-powered automated measurements and vendor-neutral data analysis to enhance diagnostic confidence and reproducibility across various ultrasound systems. It is ideal for institutions seeking a comprehensive solution for cardiac image review, analysis, and reporting with flexible deployment options.
View Ultrasound Workspace (UWS 6.0) →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if your focus is on advanced, quantitative analysis of arterial plaque composition and stability from CT angiography to improve atherosclerosis patient stratification. This system provides detailed visualization and measurement of plaque characteristics, including Lipid-Rich Necrotic Core (LRNC) and calcifications, validated against histology. It is best suited for clinicians who require precise insights into plaque vulnerability and fractional flow reserve (FFRct) to optimize treatment decisions for patients with cardiovascular disease.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Ultrasound Workspace (UWS 6.0) | ElucidVivo A.3 |
|---|---|---|
| Deployment | On-premise (single-seat workstation, multi-seat server) | Cloud and on-premise secure deployment. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Ultrasound Workspace (UWS 6.0)Ultrasound Workspace (UWS 6.0) emphasizes streamlining echocardiography workflows, enhancing diagnostic confidence, and improving reproducibility through flexible deployment options, including web-based access and consistent on- and off-cart capabilities. This focus on workflow efficiency and accessibility across various settings suggests a stronger emphasis on overall usability. ElucidVivo A.3, while offering detailed visualizations, does not highlight workflow streamlining or flexible access to the same extent.
Clinical Value
ElucidVivo A.3ElucidVivo A.3 offers highly specialized and innovative clinical value by providing quantitative analysis of arterial plaque composition (e.g., Lipid-Rich Necrotic Core) and deriving fractional flow reserve (FFRct) from CT angiography, validated against ground-truth histology. This provides unique, predictive insights for atherosclerosis patient stratification and treatment optimization. While UWS 6.0 offers valuable AI-powered automated measurements and reproducibility in echocardiography, ElucidVivo A.3's deep, histology-validated plaque analysis represents a more profound and specific clinical impact on a critical condition.
Pricing & Value
TieBoth tools require contacting the vendor for pricing information, making a direct comparison of their pricing and overall value proposition impossible without further details. While Tool A mentions 'flexible licensing models,' this is not enough to definitively declare a winner in terms of value without understanding the actual cost structures.
Enterprise Readiness
Ultrasound Workspace (UWS 6.0)Ultrasound Workspace (UWS 6.0) explicitly states it is a 'scalable technology platform' with 'flexible deployment' options, including single-seat workstations, server-client network infrastructure, and web-based access. It also explicitly confirms HIPAA compliance and the availability of a Business Associate Agreement (BAA). ElucidVivo A.3 implies HIPAA compliance and PACS/EMR integration but is less explicit about its deployment flexibility and scalability for enterprise environments.
Innovation
ElucidVivo A.3ElucidVivo A.3 demonstrates greater innovation by offering a unique quantitative analysis of arterial plaque composition and stability from CT angiography, including the objective quantification of Lipid-Rich Necrotic Core and the derivation of FFRct, which is validated against ground-truth histology. This moves beyond traditional diagnostic assistance to provide predictive insights for personalized atherosclerosis management. While UWS 6.0 utilizes AI for automated measurements and vendor-neutral analysis, ElucidVivo A.3's specialized, histology-validated approach to plaque characterization is particularly groundbreaking.
Support & Docs
Ultrasound Workspace (UWS 6.0)Philips, as a large and established medical technology company, explicitly details comprehensive support services and publicly available documentation for Ultrasound Workspace (UWS 6.0), including technical documents, release notes, and DICOM conformance statements. They also offer tailored comprehensive support and various services. In contrast, specific details regarding support offerings and documentation for ElucidVivo A.3 are not readily available in the provided information or web search results.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Ultrasound Workspace (UWS 6.0) | ElucidVivo A.3 |
|---|---|---|
| Name | Ultrasound Workspace (UWS 6.0) | ElucidVivo A.3 |
| Company | Philips Ultrasound | Elucid Bioimaging |
| Primary Focus | Holistic, scalable, AI-powered cardiovascular viewing, analysis, and reporting system designed to streamline echocardiography workflows, enhance diagnostic confidence, and improve reproducibility through vendor-neutral data analysis and flexible deployment. | FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology. |
| AI-Powered Analysis | AI-powered automated measurements (e.g., Auto Measure, AutoStrain LV, 3D Auto RV, 3D Auto MV, 3D Auto TV, 3D Auto CFQ). | AI-powered quantitative analysis of arterial plaque composition and stability from CT angiography. Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images. Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity. |
| Vendor Neutrality | Vendor-neutral and multi-vendor data analysis for standardization. | Not specified |
| Key Measurements/Output | Automated measurements (e.g., Auto Measure, AutoStrain LV, 3D Auto RV, 3D Auto MV, 3D Auto TV, 3D Auto CFQ), comprehensive cardiovascular software solutions (review, image analysis, reporting, image management). | Quantitative analysis of arterial plaque composition and stability, objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, visualizes lesion-level plaque composition, provides 3D visualization of highlighted vessels, offers rotatable curved MPR vessel views and cross-sections, aids in stratifying patients with atherosclerosis, derives fractional flow reserve (FFRct). |
Videos
Demos, reviews, and walkthroughs featuring Ultrasound Workspace (UWS 6.0) and ElucidVivo A.3.